LBA15: Rates of Pathologic Complete Response (pCR) after Datopotamab Deruxtecan (Dato) plus Durvalumab (Durva) Treatment Strategy in the Neoadjuvant Setting 

Results from the I-SPY 2.2 Trial 

Meghna S. Trivedi, MD, MS Herbert Irving Assistant Professor of Medicine Columbia University Irving Medical Center Barcelona, Spain September 14, 2024 

DECLARATION OF INTERESTS Meghna S. Trivedi MD, MS Research funding: AstraZeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Phoenix Molecular Designs (Inst); Regeneron (Inst) 

Meghna S. Trivedi, MD, MS 

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. 

Key Takeaways The ISPY 2.2 Dato + Durva treatment strategy was highly effective with an overall observed pCR rate of 50% ▪ 

▪ 

Most effective in the Immune+ subtype • 

> 50% of pCR achieved without standard chemotherapy 

• 

> 90% of pCR achieved without anthracycline 

HR-/Immune-/DRD- subtype outperformed the dynamic control 

Meghna S. Trivedi, MD, MS 

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. 

I-SPY 2.2 Design Features: Multiple Sequential Regimens 

Eligibility for Dato+Durva arm: Anatomic Stage II/III MammaPrint High risk HER2 negative 

based on Response Predictive Subtype (RPS) 

deruxtecan Dosing: 6 mg/kg Dato IV with 1120 mg Durva IV on day 1 of each 3-week cycle for up to 4 cycles 

Comparator arm: Dynamic control Specific to each subtype identified from previously tested I-SPY2 agents between March 2010 and April 2022 (e.g. paclitaxel -> AC ; paclitaxel + pembrolizumab -> AC ; paclitaxel + veliparib + carboplatin -> AC) 

Rationale: Dato + Durva in 1st line mTNBC • Preclinical data have demonstrated that Topo-I inhibitors can enhance antitumor immune responses and improve the antitumor efficacy of antiPD-L1 therapy1,2 • In the phase 1b/2 BEGONIA study, Dato + Durva had an ORR of 79% in 1st-line mTNBC3 

BEGONIA: Antitumor responses in 1st line Dato + Durva for mTNBC3 10 0 

Best change from baseline in target lesion size (%) 

2 

N=62 

Confirmed ORR: 79% (49/62; 95% CI, 66.8–88.3) Median PFS: 13.8 months; Median DoR: 15.5 months 

50 * 0 

– 50 

– 100 Progressive disease 

Stable disease 

Not evaluable 

Dotted lines indicate thresholds for partial response (−30%) and progressive disease (20%). *If the best percentage change from baseline of target lesions cannot be calculated due to progression, withdrawal, or death, the value is imputed at +20%. “•” Patients with PD as best overall response. #Unconfirmed response. (a/m)TNBC, (advanced/metastatic) triple-negative breast cancer; ADC, antibody-drug conjugate; CI, confidence interval; CR, complete response; Dato, datopotamab deruxtecan; DoR, duration of response; NC, not calculable; ORR, overall response rate; PD, progressive disease; PD-L1, programmed death ligand-1; PFS, progression-free survival; PR, partial response;; Topo-I, topoisomerase I; TROP2, trophoblast cell surface antigen 2. 

Partial response 

Complete response 

1. McKenzie JA, et al. J Natl Cancer Inst. 2018;110(7):777–86; 2. Huang KC, et al. Cancers. 2021;13(6):1218; 3. Schmid P, et al. Presented at ESMO 2023. 379MO. 

Baseline characteristics Distribution of subtypes Age (Years) at Screening Ethnicity 

Race 

Mean (SD) 

Overall (N=106) 50.5 (13.2) 

Median [Min, Max] 

50.0 [25.0, 77.0] 

Hispanic/Latino Not Hispanic/Latino Missing Asian Black White Missing 

13 (12.3%) 81 (76.4%) 12 (11.3%) 12 (11.3%) 9 (8.5%) 63 (59.4%) 22 (20.8%) 

Definitions HR: Hormone receptor status HER2: HER2 status Immune: Immunotherapy benefit DRD: DNA Damage repair deficiency 

Shatsky R et al. ASCO. 2024. 

Efficacy of treatment strategy spanning Blocks A-C 

ITT: all pts in the subtype preRCB met: sensitivity analysis of pts in the subtype who met preRCB recommendation for surgery 

Timing of observed pCR 

(includes 4 patients who met preRCB criteria for surgery) 

Number exiting block 

42 

39 

25 Total achieving pCR 

All patients (N=106) 

HER2-Immune+ (N=47) 

HR-HER2-* (N=63) * Excludes 1 patient who did not receive pembrolizumab in Block B 

N achieving pCR Cumulative % of total observed pCR N achieving pCR Cumulative % of total observed pCR N achieving pCR Cumulative % of total observed pCR 

25 

22 

6 

47% 

89% 

100% 

(25/53) 

(47/53) 

(53/53) 

20 

14 

3 

54% 

92% 

100% 

(20/37) 

(34/37) 

(37/37) 

21 

15 

3 

54% 

92% 

100% 

(21/39) 

(36/39) 

(39/39) 

53 50% (53/106) 37 79% (37/47) 39 62% (39/63) 

Incidence of most frequent non-immune adverse events Block A Alone 

iMedDra combined terms 

Blocks A-C 

1 participant (70 yo with hx of HTN) experienced a Grade 5 cardiac arrest in Block B 

Stomatitis (Combined): Stomatitis, Oropharyngeal pain, Mouth ulceration, Mouth injury, Oral pain, Mouth ulceration, Gingival pain Rash (Combined): Rash, Rash maculo-papular, Dermatitis, Rash pustular, Skin disorder, Dermatitis acneiform, Rash pruritic, Rash erythematous, Eczema, Urticaria, and Rash macular Ocular issues (Combined): Keratitis, Eye pain, Vision blurred, Eye irritation, Photophobia, Eye pruritus, Dry eye, Photopsia, Conjunctivitis, Eye infection, Eyelid irritation, Corneal ulcer, Uveitis, Corneal opacity, Eye disorder 

Immune-related adverse events 

iMedDra combined terms Hepatitis (Combined): Autoimmune hepatitis, Hepatitis, Alanine aminotransferase increased, Transaminases increased Rash (Combined): Rash, Rash maculo-papular, Dermatitis, Rash pustular, Skin disorder, Dermatitis acneiform, Rash pruritic, Rash erythematous, Eczema, Urticaria, and Rash macular Neutropenia (Combined): Febrile neutropenia, Neutropenia, and Neutrophil count decreased 

Conclusions ❑ 

The ISPY 2.2 Dato + Durva treatment strategy resulted in an overall observed pCR rate of 50% ◆ Highest pCR rate observed in Immune+ (79%) followed by TNBC (62%) subtypes ◆ > 50% of pCRs achieved by Block A alone and >90% achieved by Block B ◆ Ability to avoid taxane (Block B) and/or anthracycline (Block C) treatment 

◆ In HR-/Immune-/DRD-, the modeled pCR rate for the treatment strategy outperformed 

the dynamic control ◆ pCR rates were higher in those who met preRCB criteria 

❑ 

Reported toxicity profile of this combination was consistent with prior studies 

❑ 

Further investigation in the randomized controlled trial setting in the Immune+ and HR-/Immune-/DRD- subtypes is warranted 

Meghna S. Trivedi, MD, MS 

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. 

https://www.nature.com/articles/s41591-024-03267-1 

Acknowledgements WORKING GROUP CHAIRS Study PIs: Agents: 

L. Esserman L. Esserman, D. Yee, K. Kalinsky Statistics: C. Yau Clinical Operations C. Isaacs R. Shatsky Patient Advocates: J. Perlmutter Imaging: N. Hylton PRO/QOL: D. Hershman A. Basu Biomarkers: L. van ’t Veer 

QUANTUM LEAP HEALTHCARE COLLABORATIVE/ UCSF: Operations IP Project Oversight: A. Barker QED: A. DeMichele A. Clark E. Price Locoregional: J. Boughey R. Mukhtar Safety : H. Rugo R. Nanda Pathology: F. Symmans S. Borowsky IRB Working Group: T. Helsten 

PROJECT OVERSIGHT Anna Barker/USC; Reena Phillip/FDA; Janet Woodcock/FDA; Eric Rubin/Merck Sharp & Dohme LLC (Merck & Co, Inc), FNIH Biomarker Consortium; Lisa LaVange/UNC; Sean Khozin MIT/Phyusion; Hon Jackie Speier; Ken Cohen MD Optum Primary Care/Translational Research 

SITE PRINCIPAL INVESTIGATORS: 27 Main Sites (17 Satellite Sites) City of Hope: J. Tseng Columbia: M. Trivedi Denver: V. Borgus Emory: K. Kalinsky Georgetown: C. Isaacs HOAG: C. Nangia Huntsman: C. Vaklavas Loyola: K. Albain Mayo: J. Boughey Moffitt: H. Han Montefiore J. Anampa OSU: N. Williams OHSU: A. Zimmer Roswell Park: E. Levine 

Rutgers: C. Omene Sparrow: B. Thomas UAB: E. Stringer-Reasor UC Davis: M. Arora UChicago: R. Nanda UCSD: A. Wallace UCSF: A. Jo Chien UMN: D. Yee URMC: C. Falkson UPenn: A. Clark USC: E. Roussos Torres WakeForest: M. McNatt Yale: M. Rozenblitz 

CEO: J. Palazzolo SVP of Clinical Operations: R. Sivaramakrishna Director of Clinical Operations: M. Pitsiouni Associate Director of Clinical Operations: S. Heusbourg 

Drug Management: F. Chu, A. Spivak, A. Sangwan, J. Ritchie Collaborations P. Henderson, S. Jafari,, R. Lavieri, K. O’Grady, K. Basu UCSF Core Lab: L. Brown Swigart, S. Venters, A. Aye Ma, E. Bergin, K. Papuga, P. Glenn, L. Torres Altamirano, A. Tellier, K. Etzel 

Oncology Clinical Operations: T. Nguyen, W. Chang, H. Prisant, B. Szlanic, T. Neseth, B. UCSF Imaging Lab: Nwaogu, Z. Patel, P. Vyas, A. Snew, J. Engleman, N. Allen, J. Gibbs, M. Watkins, T. Bareng T. Blakeney, A. Lewis, J. Chineme, A. Lewis, J. Dettor, K. Timm Data Analysis, Data Management: C. Yau, P. Norwood, A. Basu, G. Peterson, A. Wilson, C. Safety: Russell, A. Glowacki, P. Beineke, I. Dunn, A. Glas M. Salem (QLHC), P. Genupala, P. Akande, M. Gunda, O. Khan Mohammed, S. Kacker, B. Perry Data Informatics IT: A. Asare, L. Weiss, N. Lim, D. Dimitru Site Regulatory: E. Guerrero, S. Rice 

Trial Design & Science Trial Design Modeling: C. Yau, D. Wolf, B. Triatis, M. Davidian 

Clinical Science: L. Esserman, D. Yee, C. Isaacs, R. Shatsky, J. Perlmutter, D. Hersman, A. Basu, A. DeMichele, A. Clark, E. Price, J.Boughy, R. Mukhtar, H. Rugo, R. Nanda, F. Symmans, Biomarkers: L. Brown Swigart, G. Hirst, E. Petricoin, J. Wulfkuhle, M. S. Borowsky, T. Helsten, L. Pusztai, A. Elias Campbell, M. Magbanua, S. Venters, A, A. Basu, R. Sayaman, C. Yau, D. Wolf, L. van ‘t Veer Patient Advocacy: J.Perlmutter Imaging: W. Li, N. Onishi, E. Price, D. Kontos, S. Partridge, P. Bolan, D. Newitt, N. Hylton 

Grants/Publications: J. Matthews R. Frieberg 

Thank you to the remarkable patients and families, our advocates, all of the investigators, staff, our DSMB and Independent Agent Selection Committee (IASC) for supporting the trial 

I-SPY 2TM TRIAL 

Participating Organizations FUNDING PARTNERS William K Bowes, Jr. Foundation Foundation for the National Institutes of Health (FNIH) Give Breast Cancer the Boot University of California San Francisco (UCSF) The Biomarkers Consortium IQVIA (formerly Quintiles) 

The Breast Cancer Research Foundation (BCRF) The Safeway Foundation California Breast Cancer Research Program Breast Cancer Research – Atwater Trust Stand Up to Cancer AstraZeneca 

INVESTIGATIONAL AGENT PROVIDERS Pfizer (Seagen) AstraZeneca Daiichi-Sankyo Merck Sharp & Dohme LLC (Merck & Co, Inc) 

Dynavax Puma Biotechnology Jazz AbbVie ALX Oncology 

Madrigal Pharmaceuticals (formerly Synta Pharmaceuticals) Genentech J&J (AMBRX) Amgen Regeneron Vyriad G1 Therapeutics Synthon 

Eli Lilly Arvinas Atossa Therapeutics Sermonix Sanofi 

DATA SUPPORT 

BIOMARKER PLATFORMS 

Oracle Argus TrialInteractive Aridhia OpenSpecimen IQVIATM Biotech OpenClinica, LLC IQVIATM Biotech 

Natera, Inc Delphi UC Davis Agendia The Translational Genomics Research Institute (TGen®) University of California San Francisco (UCSF) Illumina George Mason University (GMU) Invitae 

© 2020 Quantum Leap Healthcare Collaborative™. Confidential and Proprietary. All rights reserved. 

 